Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Risk Partners on Going Public and the capital market blog on prospectus liability
insurance

Over the past few months, we have expanded our expertise in the Prospectus liability insurance with a broad audience on two renowned platforms. Here is an overview:

  • Kapitalmarkt.blog
    In the article "POSI insurance - the protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies that are active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence.

  • GoingPublic Magazine
    In "Liability risks in uplisting and private placements", we focus on the particular risks that arise in private placements and the switch to regulated market segments. Here, too, we emphasize how well thought-out prospectus liability insurance can create the necessary security for issuers.

From our projects and the special features of POSI and D&O insurance as claims-made insurances, we know how important it is to have such an insurance program ideally in place. 24 months in advance structure. It is therefore important for us to share our knowledge and expertise so that companies are optimally prepared for the challenges.

🔍 How can we help you? Whether you are planning an IPO, preparing a private placement or want to protect your company against potential liability risks: We provide you with comprehensive advice on Prospectus liability insurance and develop the optimum solution for your requirements.

👉 Get in touch with us today!

Also read our other blog posts

Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "
Being Public

Earnings Call: one 0 too many - the Lyft CEO mistake

"Look, it was a bad mistake, and that's on me," CEO of LYFT Inc. The incident and possible insurance coverage. You may have also heard about the recent incident with LYFT. In the quarterly earnings report, LYFT originally stated that profit margins were up 500 basis points before correcting this to 50 basis points during the conference call. This clerical error caused the stock price to rise more than 60% in after-hours trading. This situation is exactly what investor relations teams that

Read more "
Risk Partners

13th Hamburg Financial Lines Forum

Risk Partners at the Financial Lines Forum 13th Hamburg Financial Lines Forum. On October 12 and 13, 2023, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that once again served as a platform for the exchange of current trends. The program began with an overview of current developments and the handling of claims in financial lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks. Dr. Oliver Sieg then shed light on directors' and officers' liability and the

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
4 pillars of cyber insurance for venture capital and private equity
Cyber Security

Cyber insurance Venture capital and private equity

Why cyber insurance does not transfer the core risk of VC & PE funds and why we have invested in Risk Partners cyber master agreements. Why cyber risks are relevant for venture capital and private equity funds With the increasing growth of the cyber crime industry (see Federal Office for the Protection of the Constitution), venture capital (VC) and private equity (PE) funds and their fund managers are also increasingly exposed to cyber risks. For years, this has been reflected in the claims we have been able to support, in which fund managers have ranked first year after year among the industries we advise.

Read more "